



## Online Supplementary Material

Cost of Anti-CD38 Monoclonal Antibodies in Combination With Bortezomib, Lenalidomide and Dexamethasone for the Frontline Treatment of Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma in the US. *JHEOR*. 2025;12(2):27-31. [doi:10.36469/jheor.2025.141714](https://doi.org/10.36469/jheor.2025.141714)

### **Table S1: Dosing Schedules Used in the CEPHEUS and IMROZ Clinical Trials**

This supplementary material has been provided by the authors to give readers additional information about their work.



**Table S1.** Dosing Schedules Used in the CEPHEUS and IMROZ Clinical Trials<sup>6,7</sup>

IMROZ	Induction phase: Cycle 1-4 (6-week cycles)																						
	Day	1	2	4	5	8	9	11	12	14	15	21	22	23	25	26	29	30	32	33	42		
	Isatuximab (10 mg/kg)	X				X <sup>a</sup>					X		X <sup>a</sup>				X						
	Bortezomib (1.3 mg/m <sup>2</sup> )	X		X		X		X					X		X		X		X				
	Lenalidomide (25 mg) <sup>b</sup>	Days 1-14													Days 22-35								
	Dexamethasone (20 mg)	X <sup>c</sup>	X	X <sup>c</sup>	X	X <sup>c</sup>	X	X <sup>c</sup>	X			X <sup>c</sup>		X <sup>c</sup>	X	X <sup>c</sup>	X	X <sup>c</sup>	X	X <sup>c</sup>	X		
	Continuous phase: Cycle 5 onward (4-week cycles) until the occurrence of disease progression, an unacceptable adverse event, or other discontinuation criteria																						
	Isatuximab (10 mg/kg), cycle 5-17	X										X											
	Isatuximab (10 mg/kg), cycle 18+	X																					
	Lenalidomide (25 mg) <sup>b</sup>	Days 1-21																					
Dexamethasone (20 mg)	X					X					X		X										
CEPHEUS	Cycle 1-8 (3-week cycles)																						
	Day	1	2	4	5	8	9	11	12	14	15	21	22	23	25	26	29	30	32	33	42		
	Daratumumab (1800 mg), cycles 1-2	X				X					X												
	Daratumumab (1800 mg), cycles 3-8	X																					
	Bortezomib (1.3 mg/m <sup>2</sup> )	X		X		X		X															
	Lenalidomide (25 mg)	Days 1-14																					
	Dexamethasone (20 mg)	X <sup>d</sup>	X	X <sup>d</sup>	X	X <sup>d</sup>	X	X <sup>d</sup>	X														
	Continuous phase: Cycle 8 onward (4-week cycles) until progression or unacceptable toxicity																						
	Daratumumab (1800 mg)	Once every 4 weeks																					
	Lenalidomide (25 mg)	Days 1-21																					
Dexamethasone (40 mg)	X <sup>e</sup>					X <sup>e</sup>						X <sup>e</sup>		X <sup>e</sup>									
*Cycle 1 only.																							
*10 mg per day if the estimated glomerular filtration rate was 30 to <60 ml per minute per 1.73 m <sup>2</sup> .																							
*Patients ≥75 years receive dexamethasone only on these days.																							
*Patients >75 years or body mass index <18.5 km/m <sup>2</sup> receive dexamethasone only on these days.																							
*20 mg for patients >75 years or body mass index <18.5 km/m <sup>2</sup> .																							